Impairment of KLF10 function is associated with lipid accumulation and alterations of glucose metabolism, suggesting that activation of the AMPK-KLF10 axis could be a potential therapeutic target for the treatment of metabolic syndrome, including NAFLD. This evidence concerns the gene KLF10 and metabolic dysfunction-associated steatotic liver disease.